C-SOLVE-2 Drug Patent Profile
✉ Email this page to a colleague
When do C-solve-2 patents expire, and when can generic versions of C-solve-2 launch?
C-solve-2 is a drug marketed by Fougera Pharms and Ivax Sub Teva Pharms and is included in two NDAs.
The generic ingredient in C-SOLVE-2 is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for C-solve-2
A generic version of C-SOLVE-2 was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for C-SOLVE-2?
- What are the global sales for C-SOLVE-2?
- What is Average Wholesale Price for C-SOLVE-2?
Summary for C-SOLVE-2
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 5,238 |
| DailyMed Link: | C-SOLVE-2 at DailyMed |
US Patents and Regulatory Information for C-SOLVE-2
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fougera Pharms | C-SOLVE-2 | erythromycin | SOLUTION;TOPICAL | 062468-001 | Jul 3, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ivax Sub Teva Pharms | C-SOLVE-2 | erythromycin | SWAB;TOPICAL | 062751-001 | Jul 30, 1993 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
